Information Provided By: 
Fly News Breaks for February 13, 2018
MNTA, TEVA
Feb 13, 2018 | 10:21 EDT
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
News For TEVA;MNTA From the Last 2 Days
There are no results for your query TEVA;MNTA
